MedPath

Alessa Therapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:1
Completed:1

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Phase 1
Recruiting
Conditions
Prostate Adenocarcinoma
Interventions
First Posted Date
2024-02-14
Last Posted Date
2024-06-28
Lead Sponsor
Alessa Therapeutics Inc.
Target Recruit Count
20
Registration Number
NCT06257693
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

Phase 1
Active, not recruiting
Conditions
Prostate Adenocarcinoma
Interventions
Radiation: Stereotactic body radiation therapy
First Posted Date
2021-06-29
Last Posted Date
2025-05-14
Lead Sponsor
Alessa Therapeutics Inc.
Target Recruit Count
20
Registration Number
NCT04943536
Locations
🇺🇸

National Cancer Institute, Bethesda, Maryland, United States

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Phase 1
Completed
Conditions
Prostate Adenocarcinoma
Lower Urinary Tract Symptoms
First Posted Date
2020-02-26
Last Posted Date
2024-06-24
Lead Sponsor
Alessa Therapeutics Inc.
Target Recruit Count
17
Registration Number
NCT04284761
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇦🇺

Australian Clinical Trials, Wahroonga, New South Wales, Australia

🇦🇺

University of Wollongong, Wollongong, New South Wales, Australia

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.